Literature DB >> 9134203

Speech dysfunction due to trazodone--fluoxetine combination in traumatic brain injury.

D E Patterson1, S E Braverman, P V Belandres.   

Abstract

New serotonin reuptake inhibitors are available for the treatment of affective disorders and sleep dysfunction in traumatic brain injury (TBI) patients. Commonly reported serotonergic side-effects include nausea, headache, dizziness, nervousness and orthostatic hypotension. Trazodone, a non-selective serotonin reuptake inhibitor, is often used in conjunction with fluoxetine, a selective serotonin reuptake inhibitor, in order to combat the insomnia associated with fluoxetine. Successful use of this combination is generally limited by the cumulative serotonergic side-effects of the two medications. This paper describes the first reported case of speech dysfunction as a complication of combined trazodone and fluoxetine use. A 43-year-old male suffered bilateral wrist fractures and a moderate TBI during a fall. Within 1 week of adding fluoxetine to trazodone the patient developed new-onset dysarthria and speech blocking. Upon discontinuation of fluoxetine, speech returned to normal. Possible mechanisms include inhibition of hepatic metabolism, unmasking of caudate nucleus injury, increased noradrenergic activity or previously unreported serotonergic effects. This case illustrates the importance of monitoring drug combinations for unexpected side-effects in the TBI population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9134203     DOI: 10.1080/026990597123593

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  3 in total

1.  Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury.

Authors:  Yonggang Wang; Melanie Neumann; Katharina Hansen; Shuwhey M Hong; Sharon Kim; Linda J Noble-Haeusslein; Jialing Liu
Journal:  J Neurotrauma       Date:  2011-02       Impact factor: 5.269

2.  Amphetamine analogs methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) differentially affect speech.

Authors:  Gina F Marrone; Jennifer S Pardo; Robert M Krauss; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2009-11-17       Impact factor: 4.530

Review 3.  Selective Serotonin Reuptake Inhibitors for Treating Neurocognitive and Neuropsychiatric Disorders Following Traumatic Brain Injury: An Evaluation of Current Evidence.

Authors:  John K Yue; John F Burke; Pavan S Upadhyayula; Ethan A Winkler; Hansen Deng; Caitlin K Robinson; Romain Pirracchio; Catherine G Suen; Sourabh Sharma; Adam R Ferguson; Laura B Ngwenya; Murray B Stein; Geoffrey T Manley; Phiroz E Tarapore
Journal:  Brain Sci       Date:  2017-07-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.